nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisuride—DRD4—obesity	0.077	0.189	CbGaD
Lisuride—HTR1B—obesity	0.0684	0.168	CbGaD
Lisuride—DRD1—obesity	0.0651	0.16	CbGaD
Lisuride—ADRB1—obesity	0.0605	0.148	CbGaD
Lisuride—HTR2C—obesity	0.0557	0.137	CbGaD
Lisuride—ADRA1B—Phendimetrazine—obesity	0.0502	0.139	CbGbCtD
Lisuride—DRD2—obesity	0.0459	0.113	CbGaD
Lisuride—DRD1—Phenylpropanolamine—obesity	0.0453	0.125	CbGbCtD
Lisuride—ADRB1—Phenylpropanolamine—obesity	0.039	0.108	CbGbCtD
Lisuride—ADRA2C—Methamphetamine—obesity	0.038	0.105	CbGbCtD
Lisuride—ADRA2B—Methamphetamine—obesity	0.036	0.0996	CbGbCtD
Lisuride—HTR2A—obesity	0.0355	0.087	CbGaD
Lisuride—ADRA2A—Benzphetamine—obesity	0.0313	0.0867	CbGbCtD
Lisuride—ADRA2A—Phenylpropanolamine—obesity	0.0299	0.0827	CbGbCtD
Lisuride—ADRA2A—Methamphetamine—obesity	0.025	0.0693	CbGbCtD
Lisuride—Mental disorder due to a general medical condition—Cimetidine—obesity	0.0135	0.124	CcSEcCtD
Lisuride—Organic brain syndrome—Cimetidine—obesity	0.0135	0.124	CcSEcCtD
Lisuride—CYP2D6—Phentermine—obesity	0.0104	0.0288	CbGbCtD
Lisuride—CYP2D6—Bupropion—obesity	0.00886	0.0245	CbGbCtD
Lisuride—CYP3A4—Sibutramine—obesity	0.00874	0.0242	CbGbCtD
Lisuride—CYP2D6—Methamphetamine—obesity	0.00833	0.023	CbGbCtD
Lisuride—Cardiac valve disease—Benzphetamine—obesity	0.00803	0.0735	CcSEcCtD
Lisuride—Cardiac valve disease—Phendimetrazine—obesity	0.00732	0.067	CcSEcCtD
Lisuride—CYP3A4—Benzphetamine—obesity	0.00662	0.0183	CbGbCtD
Lisuride—CYP2D6—Cimetidine—obesity	0.0065	0.018	CbGbCtD
Lisuride—Cardiac valve disease—Phentermine—obesity	0.00598	0.0548	CcSEcCtD
Lisuride—CYP3A4—Bupropion—obesity	0.00563	0.0156	CbGbCtD
Lisuride—Cardiac valve disease—Diethylpropion—obesity	0.0052	0.0477	CcSEcCtD
Lisuride—CYP3A4—Orlistat—obesity	0.00459	0.0127	CbGbCtD
Lisuride—CYP3A4—Cimetidine—obesity	0.00413	0.0114	CbGbCtD
Lisuride—CYP3A4—Topiramate—obesity	0.00271	0.00749	CbGbCtD
Lisuride—Blood pressure increased—Phendimetrazine—obesity	0.0012	0.011	CcSEcCtD
Lisuride—Blood pressure increased—Phenylpropanolamine—obesity	0.00103	0.0094	CcSEcCtD
Lisuride—HTR2A—sympathetic nervous system—obesity	0.000966	0.0894	CbGeAlD
Lisuride—HTR2A—vagus nerve—obesity	0.000935	0.0866	CbGeAlD
Lisuride—Blood pressure increased—Diethylpropion—obesity	0.000854	0.00782	CcSEcCtD
Lisuride—Peripheral coldness—Bupropion—obesity	0.000795	0.00728	CcSEcCtD
Lisuride—Myoclonus—Sibutramine—obesity	0.000722	0.00661	CcSEcCtD
Lisuride—Libido increased—Sibutramine—obesity	0.000714	0.00654	CcSEcCtD
Lisuride—Sweating—Benzphetamine—obesity	0.000707	0.00647	CcSEcCtD
Lisuride—Disorientation—Cimetidine—obesity	0.000659	0.00604	CcSEcCtD
Lisuride—HTR2A—autonomic nervous system—obesity	0.000649	0.0601	CbGeAlD
Lisuride—Sweating—Phendimetrazine—obesity	0.000644	0.0059	CcSEcCtD
Lisuride—Myoclonus—Bupropion—obesity	0.000629	0.00576	CcSEcCtD
Lisuride—Libido increased—Bupropion—obesity	0.000622	0.0057	CcSEcCtD
Lisuride—Palpitations—Methamphetamine—obesity	0.000528	0.00484	CcSEcCtD
Lisuride—Abdominal discomfort—Diethylpropion—obesity	0.000514	0.00471	CcSEcCtD
Lisuride—Hallucination—Phenylpropanolamine—obesity	0.000513	0.0047	CcSEcCtD
Lisuride—Palpitations—Benzphetamine—obesity	0.000509	0.00466	CcSEcCtD
Lisuride—Peripheral coldness—Topiramate—obesity	0.000506	0.00464	CcSEcCtD
Lisuride—Hallucination—Phentermine—obesity	0.00049	0.00449	CcSEcCtD
Lisuride—Tachycardia—Methamphetamine—obesity	0.000476	0.00436	CcSEcCtD
Lisuride—Palpitations—Phendimetrazine—obesity	0.000464	0.00425	CcSEcCtD
Lisuride—HTR1A—hindbrain—obesity	0.000459	0.0425	CbGeAlD
Lisuride—Tachycardia—Benzphetamine—obesity	0.000459	0.0042	CcSEcCtD
Lisuride—Hyperhidrosis—Benzphetamine—obesity	0.000454	0.00416	CcSEcCtD
Lisuride—Anorexia—Benzphetamine—obesity	0.000448	0.0041	CcSEcCtD
Lisuride—Insomnia—Methamphetamine—obesity	0.000441	0.00404	CcSEcCtD
Lisuride—Blood pressure increased—Sibutramine—obesity	0.000434	0.00398	CcSEcCtD
Lisuride—Aggression—Bupropion—obesity	0.000431	0.00395	CcSEcCtD
Lisuride—Insomnia—Benzphetamine—obesity	0.000425	0.00389	CcSEcCtD
Lisuride—Gastrointestinal disorder—Methamphetamine—obesity	0.000421	0.00386	CcSEcCtD
Lisuride—Nightmare—Sibutramine—obesity	0.000419	0.00384	CcSEcCtD
Lisuride—Tachycardia—Phendimetrazine—obesity	0.000418	0.00383	CcSEcCtD
Lisuride—Constipation—Methamphetamine—obesity	0.000417	0.00382	CcSEcCtD
Lisuride—DRD2—hindbrain—obesity	0.000415	0.0384	CbGeAlD
Lisuride—Hyperhidrosis—Phendimetrazine—obesity	0.000414	0.00379	CcSEcCtD
Lisuride—Decreased appetite—Benzphetamine—obesity	0.000409	0.00374	CcSEcCtD
Lisuride—Anorexia—Phendimetrazine—obesity	0.000408	0.00374	CcSEcCtD
Lisuride—Hallucination—Cimetidine—obesity	0.000406	0.00372	CcSEcCtD
Lisuride—Gastrointestinal disorder—Benzphetamine—obesity	0.000406	0.00372	CcSEcCtD
Lisuride—Libido increased—Topiramate—obesity	0.000396	0.00363	CcSEcCtD
Lisuride—Insomnia—Phendimetrazine—obesity	0.000388	0.00355	CcSEcCtD
Lisuride—Anxiety—Phenylpropanolamine—obesity	0.00038	0.00349	CcSEcCtD
Lisuride—Palpitations—Phentermine—obesity	0.000379	0.00347	CcSEcCtD
Lisuride—Blood pressure increased—Bupropion—obesity	0.000379	0.00347	CcSEcCtD
Lisuride—Decreased appetite—Phendimetrazine—obesity	0.000372	0.00341	CcSEcCtD
Lisuride—Confusional state—Phenylpropanolamine—obesity	0.000369	0.00338	CcSEcCtD
Lisuride—Constipation—Phendimetrazine—obesity	0.000366	0.00336	CcSEcCtD
Lisuride—Nightmare—Bupropion—obesity	0.000365	0.00335	CcSEcCtD
Lisuride—Dry mouth—Phentermine—obesity	0.000357	0.00327	CcSEcCtD
Lisuride—Tachycardia—Phenylpropanolamine—obesity	0.000357	0.00327	CcSEcCtD
Lisuride—Tachycardia—Phentermine—obesity	0.000342	0.00313	CcSEcCtD
Lisuride—Insomnia—Phenylpropanolamine—obesity	0.000331	0.00303	CcSEcCtD
Lisuride—Palpitations—Diethylpropion—obesity	0.00033	0.00302	CcSEcCtD
Lisuride—Dyspnoea—Phenylpropanolamine—obesity	0.000326	0.00299	CcSEcCtD
Lisuride—Somnolence—Phenylpropanolamine—obesity	0.000325	0.00298	CcSEcCtD
Lisuride—Dizziness—Methamphetamine—obesity	0.000322	0.00295	CcSEcCtD
Lisuride—Insomnia—Phentermine—obesity	0.000317	0.0029	CcSEcCtD
Lisuride—Anxiety—Diethylpropion—obesity	0.000317	0.0029	CcSEcCtD
Lisuride—Constipation—Phenylpropanolamine—obesity	0.000313	0.00287	CcSEcCtD
Lisuride—Disturbance in sexual arousal—Sibutramine—obesity	0.000313	0.00286	CcSEcCtD
Lisuride—Dizziness—Benzphetamine—obesity	0.000311	0.00285	CcSEcCtD
Lisuride—Dry mouth—Diethylpropion—obesity	0.000311	0.00285	CcSEcCtD
Lisuride—Disorientation—Bupropion—obesity	0.000307	0.00281	CcSEcCtD
Lisuride—Headache—Methamphetamine—obesity	0.000305	0.0028	CcSEcCtD
Lisuride—Gastrointestinal disorder—Phentermine—obesity	0.000302	0.00277	CcSEcCtD
Lisuride—Fatigue—Phentermine—obesity	0.000302	0.00277	CcSEcCtD
Lisuride—Feeling abnormal—Phenylpropanolamine—obesity	0.000302	0.00276	CcSEcCtD
Lisuride—Anxiety—Cimetidine—obesity	0.000301	0.00276	CcSEcCtD
Lisuride—Constipation—Phentermine—obesity	0.000299	0.00274	CcSEcCtD
Lisuride—Tachycardia—Diethylpropion—obesity	0.000297	0.00272	CcSEcCtD
Lisuride—DRD5—endocrine gland—obesity	0.000295	0.0273	CbGeAlD
Lisuride—Hyperhidrosis—Diethylpropion—obesity	0.000295	0.0027	CcSEcCtD
Lisuride—Headache—Benzphetamine—obesity	0.000294	0.0027	CcSEcCtD
Lisuride—Dehydration—Sibutramine—obesity	0.000293	0.00268	CcSEcCtD
Lisuride—Confusional state—Cimetidine—obesity	0.000292	0.00268	CcSEcCtD
Lisuride—Orthostatic hypotension—Sibutramine—obesity	0.000288	0.00264	CcSEcCtD
Lisuride—Dizziness—Phendimetrazine—obesity	0.000283	0.0026	CcSEcCtD
Lisuride—Tachycardia—Cimetidine—obesity	0.000283	0.00259	CcSEcCtD
Lisuride—Insomnia—Diethylpropion—obesity	0.000276	0.00252	CcSEcCtD
Lisuride—Aggression—Topiramate—obesity	0.000274	0.00251	CcSEcCtD
Lisuride—HTR2A—hindbrain—obesity	0.000273	0.0253	CbGeAlD
Lisuride—Disturbance in sexual arousal—Bupropion—obesity	0.000273	0.0025	CcSEcCtD
Lisuride—Dyspnoea—Diethylpropion—obesity	0.000272	0.00249	CcSEcCtD
Lisuride—Somnolence—Diethylpropion—obesity	0.000271	0.00248	CcSEcCtD
Lisuride—Abdominal discomfort—Orlistat—obesity	0.00027	0.00247	CcSEcCtD
Lisuride—Headache—Phendimetrazine—obesity	0.000268	0.00246	CcSEcCtD
Lisuride—HTR1B—cardiovascular system—obesity	0.000266	0.0246	CbGeAlD
Lisuride—Gastrointestinal disorder—Diethylpropion—obesity	0.000263	0.00241	CcSEcCtD
Lisuride—HTR2B—adrenal cortex—obesity	0.000262	0.0243	CbGeAlD
Lisuride—Constipation—Diethylpropion—obesity	0.000261	0.00239	CcSEcCtD
Lisuride—Somnolence—Cimetidine—obesity	0.000258	0.00236	CcSEcCtD
Lisuride—HTR1D—cardiovascular system—obesity	0.000258	0.0238	CbGeAlD
Lisuride—Dehydration—Bupropion—obesity	0.000256	0.00234	CcSEcCtD
Lisuride—DRD2—respiratory system—obesity	0.000253	0.0234	CbGeAlD
Lisuride—Asthenia—Phentermine—obesity	0.000251	0.0023	CcSEcCtD
Lisuride—Feeling abnormal—Diethylpropion—obesity	0.000251	0.0023	CcSEcCtD
Lisuride—Orthostatic hypotension—Bupropion—obesity	0.000251	0.0023	CcSEcCtD
Lisuride—ADRB1—cardiovascular system—obesity	0.00025	0.0232	CbGeAlD
Lisuride—Fatigue—Cimetidine—obesity	0.00025	0.00229	CcSEcCtD
Lisuride—CYP2D6—hindbrain—obesity	0.000249	0.0231	CbGeAlD
Lisuride—Constipation—Cimetidine—obesity	0.000248	0.00227	CcSEcCtD
Lisuride—Weight increased—Sibutramine—obesity	0.000248	0.00227	CcSEcCtD
Lisuride—Cabergoline—DRD4—obesity	0.000243	0.0634	CrCbGaD
Lisuride—Dizziness—Phenylpropanolamine—obesity	0.000242	0.00222	CcSEcCtD
Lisuride—HTR2B—cardiovascular system—obesity	0.00024	0.0222	CbGeAlD
Lisuride—Feeling abnormal—Cimetidine—obesity	0.000239	0.00219	CcSEcCtD
Lisuride—ADRA1D—endocrine gland—obesity	0.000236	0.0219	CbGeAlD
Lisuride—Sweating—Sibutramine—obesity	0.000233	0.00213	CcSEcCtD
Lisuride—Vomiting—Phenylpropanolamine—obesity	0.000233	0.00213	CcSEcCtD
Lisuride—Dizziness—Phentermine—obesity	0.000232	0.00212	CcSEcCtD
Lisuride—Abdominal discomfort—Bupropion—obesity	0.000228	0.00209	CcSEcCtD
Lisuride—Vomiting—Phentermine—obesity	0.000223	0.00204	CcSEcCtD
Lisuride—Oedema peripheral—Orlistat—obesity	0.000222	0.00203	CcSEcCtD
Lisuride—ADRB1—adipose tissue—obesity	0.000221	0.0204	CbGeAlD
Lisuride—Headache—Phentermine—obesity	0.000219	0.00201	CcSEcCtD
Lisuride—Weight increased—Bupropion—obesity	0.000216	0.00198	CcSEcCtD
Lisuride—Cabergoline—HTR1B—obesity	0.000216	0.0564	CrCbGaD
Lisuride—Weight decreased—Bupropion—obesity	0.000215	0.00197	CcSEcCtD
Lisuride—Oedema peripheral—Sibutramine—obesity	0.000215	0.00197	CcSEcCtD
Lisuride—HTR1A—cardiovascular system—obesity	0.000215	0.0199	CbGeAlD
Lisuride—HTR2B—adipose tissue—obesity	0.000211	0.0196	CbGeAlD
Lisuride—ADRA2A—islet of Langerhans—obesity	0.000208	0.0193	CbGeAlD
Lisuride—Asthenia—Cimetidine—obesity	0.000208	0.00191	CcSEcCtD
Lisuride—ADRA2C—adrenal cortex—obesity	0.000207	0.0191	CbGeAlD
Lisuride—Cabergoline—DRD1—obesity	0.000206	0.0537	CrCbGaD
Lisuride—Methylergometrine—DRD1—obesity	0.000206	0.0537	CrCbGaD
Lisuride—Immune system disorder—Orlistat—obesity	0.000203	0.00186	CcSEcCtD
Lisuride—Mediastinal disorder—Orlistat—obesity	0.000203	0.00186	CcSEcCtD
Lisuride—Sweating—Bupropion—obesity	0.000203	0.00186	CcSEcCtD
Lisuride—Dizziness—Diethylpropion—obesity	0.000201	0.00185	CcSEcCtD
Lisuride—Ergonovine—HTR2C—obesity	0.000201	0.0526	CrCbGaD
Lisuride—HTR2B—digestive system—obesity	0.000199	0.0184	CbGeAlD
Lisuride—Angiopathy—Sibutramine—obesity	0.000198	0.00181	CcSEcCtD
Lisuride—Mental disorder—Orlistat—obesity	0.000197	0.00181	CcSEcCtD
Lisuride—Immune system disorder—Sibutramine—obesity	0.000197	0.0018	CcSEcCtD
Lisuride—Malnutrition—Orlistat—obesity	0.000196	0.0018	CcSEcCtD
Lisuride—Disorientation—Topiramate—obesity	0.000196	0.00179	CcSEcCtD
Lisuride—Vomiting—Diethylpropion—obesity	0.000194	0.00177	CcSEcCtD
Lisuride—Dizziness—Cimetidine—obesity	0.000192	0.00176	CcSEcCtD
Lisuride—Headache—Diethylpropion—obesity	0.000191	0.00175	CcSEcCtD
Lisuride—Cabergoline—ADRB1—obesity	0.000191	0.0499	CrCbGaD
Lisuride—Malnutrition—Sibutramine—obesity	0.00019	0.00174	CcSEcCtD
Lisuride—HTR2B—adrenal gland—obesity	0.000189	0.0175	CbGeAlD
Lisuride—Hallucination—Bupropion—obesity	0.000189	0.00173	CcSEcCtD
Lisuride—Pergolide—DRD4—obesity	0.000188	0.049	CrCbGaD
Lisuride—Oedema peripheral—Bupropion—obesity	0.000187	0.00172	CcSEcCtD
Lisuride—Vomiting—Cimetidine—obesity	0.000184	0.00169	CcSEcCtD
Lisuride—HTR1B—endocrine gland—obesity	0.000182	0.0169	CbGeAlD
Lisuride—Headache—Cimetidine—obesity	0.000182	0.00166	CcSEcCtD
Lisuride—Methysergide—HTR1B—obesity	0.00018	0.047	CrCbGaD
Lisuride—Cardiac disorder—Bupropion—obesity	0.000176	0.00162	CcSEcCtD
Lisuride—Vertigo—Orlistat—obesity	0.000176	0.00161	CcSEcCtD
Lisuride—Cabergoline—HTR2C—obesity	0.000176	0.0459	CrCbGaD
Lisuride—Methylergometrine—HTR2C—obesity	0.000176	0.0459	CrCbGaD
Lisuride—Disturbance in sexual arousal—Topiramate—obesity	0.000174	0.00159	CcSEcCtD
Lisuride—Palpitations—Orlistat—obesity	0.000173	0.00159	CcSEcCtD
Lisuride—Angiopathy—Bupropion—obesity	0.000172	0.00158	CcSEcCtD
Lisuride—DRD2—pituitary gland—obesity	0.000172	0.0159	CbGeAlD
Lisuride—Immune system disorder—Bupropion—obesity	0.000172	0.00157	CcSEcCtD
Lisuride—ADRB1—endocrine gland—obesity	0.000172	0.0159	CbGeAlD
Lisuride—Mediastinal disorder—Bupropion—obesity	0.000171	0.00157	CcSEcCtD
Lisuride—Cough—Orlistat—obesity	0.000171	0.00157	CcSEcCtD
Lisuride—Vertigo—Sibutramine—obesity	0.000171	0.00156	CcSEcCtD
Lisuride—Syncope—Sibutramine—obesity	0.00017	0.00156	CcSEcCtD
Lisuride—HTR1A—adrenal gland—obesity	0.00017	0.0157	CbGeAlD
Lisuride—Palpitations—Sibutramine—obesity	0.000168	0.00154	CcSEcCtD
Lisuride—HTR2A—respiratory system—obesity	0.000167	0.0155	CbGeAlD
Lisuride—ADRA2C—pituitary gland—obesity	0.000167	0.0155	CbGeAlD
Lisuride—Pergolide—HTR1B—obesity	0.000167	0.0436	CrCbGaD
Lisuride—Mental disorder—Bupropion—obesity	0.000167	0.00153	CcSEcCtD
Lisuride—Anxiety—Orlistat—obesity	0.000166	0.00152	CcSEcCtD
Lisuride—ADRA2C—adipose tissue—obesity	0.000166	0.0154	CbGeAlD
Lisuride—Cough—Sibutramine—obesity	0.000166	0.00152	CcSEcCtD
Lisuride—Malnutrition—Bupropion—obesity	0.000165	0.00152	CcSEcCtD
Lisuride—Dry mouth—Orlistat—obesity	0.000163	0.0015	CcSEcCtD
Lisuride—Dehydration—Topiramate—obesity	0.000163	0.00149	CcSEcCtD
Lisuride—Anxiety—Sibutramine—obesity	0.000161	0.00148	CcSEcCtD
Lisuride—Cabergoline—ADRB2—obesity	0.00016	0.0419	CrCbGaD
Lisuride—Orthostatic hypotension—Topiramate—obesity	0.00016	0.00146	CcSEcCtD
Lisuride—Infection—Orlistat—obesity	0.000159	0.00146	CcSEcCtD
Lisuride—Pergolide—DRD1—obesity	0.000159	0.0415	CrCbGaD
Lisuride—Dry mouth—Sibutramine—obesity	0.000158	0.00145	CcSEcCtD
Lisuride—Nervous system disorder—Orlistat—obesity	0.000157	0.00144	CcSEcCtD
Lisuride—Confusional state—Sibutramine—obesity	0.000156	0.00143	CcSEcCtD
Lisuride—Hyperhidrosis—Orlistat—obesity	0.000155	0.00142	CcSEcCtD
Lisuride—Infection—Sibutramine—obesity	0.000154	0.00141	CcSEcCtD
Lisuride—Tachycardia—Sibutramine—obesity	0.000151	0.00138	CcSEcCtD
Lisuride—Hyperhidrosis—Sibutramine—obesity	0.00015	0.00137	CcSEcCtD
Lisuride—ADRA2C—adrenal gland—obesity	0.000149	0.0138	CbGeAlD
Lisuride—Vertigo—Bupropion—obesity	0.000149	0.00136	CcSEcCtD
Lisuride—Syncope—Bupropion—obesity	0.000148	0.00136	CcSEcCtD
Lisuride—Anorexia—Sibutramine—obesity	0.000148	0.00135	CcSEcCtD
Lisuride—HTR1A—endocrine gland—obesity	0.000147	0.0136	CbGeAlD
Lisuride—Methysergide—HTR2C—obesity	0.000147	0.0383	CrCbGaD
Lisuride—Palpitations—Bupropion—obesity	0.000146	0.00134	CcSEcCtD
Lisuride—Abdominal discomfort—Topiramate—obesity	0.000145	0.00133	CcSEcCtD
Lisuride—Cabergoline—DRD2—obesity	0.000145	0.0379	CrCbGaD
Lisuride—Insomnia—Orlistat—obesity	0.000145	0.00133	CcSEcCtD
Lisuride—Cough—Bupropion—obesity	0.000144	0.00132	CcSEcCtD
Lisuride—Anxiety—Bupropion—obesity	0.00014	0.00129	CcSEcCtD
Lisuride—Insomnia—Sibutramine—obesity	0.00014	0.00128	CcSEcCtD
Lisuride—Decreased appetite—Orlistat—obesity	0.000139	0.00127	CcSEcCtD
Lisuride—Ergotamine—HTR1B—obesity	0.000139	0.0363	CrCbGaD
Lisuride—Gastrointestinal disorder—Orlistat—obesity	0.000138	0.00127	CcSEcCtD
Lisuride—Dyspnoea—Sibutramine—obesity	0.000138	0.00127	CcSEcCtD
Lisuride—Fatigue—Orlistat—obesity	0.000138	0.00126	CcSEcCtD
Lisuride—Dry mouth—Bupropion—obesity	0.000138	0.00126	CcSEcCtD
Lisuride—Somnolence—Sibutramine—obesity	0.000138	0.00126	CcSEcCtD
Lisuride—Weight increased—Topiramate—obesity	0.000138	0.00126	CcSEcCtD
Lisuride—Weight decreased—Topiramate—obesity	0.000137	0.00125	CcSEcCtD
Lisuride—Confusional state—Bupropion—obesity	0.000136	0.00125	CcSEcCtD
Lisuride—Pergolide—HTR2C—obesity	0.000136	0.0355	CrCbGaD
Lisuride—Decreased appetite—Sibutramine—obesity	0.000135	0.00123	CcSEcCtD
Lisuride—Infection—Bupropion—obesity	0.000134	0.00123	CcSEcCtD
Lisuride—Gastrointestinal disorder—Sibutramine—obesity	0.000134	0.00123	CcSEcCtD
Lisuride—ADRA2A—pituitary gland—obesity	0.000133	0.0123	CbGeAlD
Lisuride—DRD2—endocrine gland—obesity	0.000133	0.0123	CbGeAlD
Lisuride—ADRA2A—adipose tissue—obesity	0.000133	0.0123	CbGeAlD
Lisuride—Constipation—Sibutramine—obesity	0.000132	0.00121	CcSEcCtD
Lisuride—Nervous system disorder—Bupropion—obesity	0.000132	0.00121	CcSEcCtD
Lisuride—Feeling abnormal—Orlistat—obesity	0.000132	0.00121	CcSEcCtD
Lisuride—Tachycardia—Bupropion—obesity	0.000132	0.00121	CcSEcCtD
Lisuride—Hyperhidrosis—Bupropion—obesity	0.000131	0.0012	CcSEcCtD
Lisuride—Anorexia—Bupropion—obesity	0.000129	0.00118	CcSEcCtD
Lisuride—HTR2A—cardiovascular system—obesity	0.000128	0.0118	CbGeAlD
Lisuride—Feeling abnormal—Sibutramine—obesity	0.000128	0.00117	CcSEcCtD
Lisuride—Insomnia—Bupropion—obesity	0.000122	0.00112	CcSEcCtD
Lisuride—Hallucination—Topiramate—obesity	0.00012	0.0011	CcSEcCtD
Lisuride—Dyspnoea—Bupropion—obesity	0.00012	0.0011	CcSEcCtD
Lisuride—Somnolence—Bupropion—obesity	0.00012	0.0011	CcSEcCtD
Lisuride—Oedema peripheral—Topiramate—obesity	0.000119	0.00109	CcSEcCtD
Lisuride—ADRA2A—adrenal gland—obesity	0.000119	0.011	CbGeAlD
Lisuride—Decreased appetite—Bupropion—obesity	0.000117	0.00108	CcSEcCtD
Lisuride—ADRA2C—liver—obesity	0.000117	0.0108	CbGeAlD
Lisuride—Gastrointestinal disorder—Bupropion—obesity	0.000117	0.00107	CcSEcCtD
Lisuride—Fatigue—Bupropion—obesity	0.000116	0.00107	CcSEcCtD
Lisuride—Constipation—Bupropion—obesity	0.000115	0.00106	CcSEcCtD
Lisuride—Asthenia—Orlistat—obesity	0.000115	0.00105	CcSEcCtD
Lisuride—Ergotamine—HTR2C—obesity	0.000113	0.0296	CrCbGaD
Lisuride—HTR2A—pituitary gland—obesity	0.000113	0.0105	CbGeAlD
Lisuride—Cardiac disorder—Topiramate—obesity	0.000112	0.00103	CcSEcCtD
Lisuride—Pergolide—DRD2—obesity	0.000112	0.0293	CrCbGaD
Lisuride—Methylergometrine—HTR2A—obesity	0.000112	0.0293	CrCbGaD
Lisuride—Cabergoline—HTR2A—obesity	0.000112	0.0293	CrCbGaD
Lisuride—Feeling abnormal—Bupropion—obesity	0.000111	0.00102	CcSEcCtD
Lisuride—Asthenia—Sibutramine—obesity	0.000111	0.00102	CcSEcCtD
Lisuride—Angiopathy—Topiramate—obesity	0.00011	0.00101	CcSEcCtD
Lisuride—Immune system disorder—Topiramate—obesity	0.000109	0.001	CcSEcCtD
Lisuride—Mediastinal disorder—Topiramate—obesity	0.000109	0.001	CcSEcCtD
Lisuride—HTR2A—digestive system—obesity	0.000106	0.00983	CbGeAlD
Lisuride—Mental disorder—Topiramate—obesity	0.000106	0.000972	CcSEcCtD
Lisuride—Dizziness—Orlistat—obesity	0.000106	0.00097	CcSEcCtD
Lisuride—Malnutrition—Topiramate—obesity	0.000105	0.000966	CcSEcCtD
Lisuride—ADRA2A—endocrine gland—obesity	0.000103	0.00955	CbGeAlD
Lisuride—Dizziness—Sibutramine—obesity	0.000102	0.000938	CcSEcCtD
Lisuride—Vomiting—Orlistat—obesity	0.000102	0.000932	CcSEcCtD
Lisuride—HTR2A—adrenal gland—obesity	0.000101	0.00937	CbGeAlD
Lisuride—Headache—Orlistat—obesity	0.0001	0.000919	CcSEcCtD
Lisuride—Vomiting—Sibutramine—obesity	9.85e-05	0.000902	CcSEcCtD
Lisuride—CYP3A4—digestive system—obesity	9.83e-05	0.0091	CbGeAlD
Lisuride—Headache—Sibutramine—obesity	9.7e-05	0.000889	CcSEcCtD
Lisuride—Asthenia—Bupropion—obesity	9.69e-05	0.000888	CcSEcCtD
Lisuride—CYP2D6—digestive system—obesity	9.67e-05	0.00896	CbGeAlD
Lisuride—Vertigo—Topiramate—obesity	9.47e-05	0.000868	CcSEcCtD
Lisuride—Syncope—Topiramate—obesity	9.45e-05	0.000866	CcSEcCtD
Lisuride—Methysergide—HTR2A—obesity	9.35e-05	0.0244	CrCbGaD
Lisuride—Ergotamine—DRD2—obesity	9.34e-05	0.0244	CrCbGaD
Lisuride—Palpitations—Topiramate—obesity	9.32e-05	0.000853	CcSEcCtD
Lisuride—Cough—Topiramate—obesity	9.2e-05	0.000843	CcSEcCtD
Lisuride—Anxiety—Topiramate—obesity	8.94e-05	0.000819	CcSEcCtD
Lisuride—Dizziness—Bupropion—obesity	8.93e-05	0.000818	CcSEcCtD
Lisuride—Dry mouth—Topiramate—obesity	8.78e-05	0.000804	CcSEcCtD
Lisuride—HTR2A—endocrine gland—obesity	8.77e-05	0.00812	CbGeAlD
Lisuride—Confusional state—Topiramate—obesity	8.67e-05	0.000795	CcSEcCtD
Lisuride—Pergolide—HTR2A—obesity	8.65e-05	0.0226	CrCbGaD
Lisuride—Vomiting—Bupropion—obesity	8.59e-05	0.000787	CcSEcCtD
Lisuride—Infection—Topiramate—obesity	8.55e-05	0.000783	CcSEcCtD
Lisuride—Headache—Bupropion—obesity	8.46e-05	0.000775	CcSEcCtD
Lisuride—Nervous system disorder—Topiramate—obesity	8.44e-05	0.000773	CcSEcCtD
Lisuride—Tachycardia—Topiramate—obesity	8.4e-05	0.000769	CcSEcCtD
Lisuride—Hyperhidrosis—Topiramate—obesity	8.32e-05	0.000762	CcSEcCtD
Lisuride—Anorexia—Topiramate—obesity	8.2e-05	0.000751	CcSEcCtD
Lisuride—CYP3A4—endocrine gland—obesity	8.12e-05	0.00752	CbGeAlD
Lisuride—CYP2D6—endocrine gland—obesity	7.99e-05	0.0074	CbGeAlD
Lisuride—HTR2A—liver—obesity	7.91e-05	0.00732	CbGeAlD
Lisuride—Insomnia—Topiramate—obesity	7.78e-05	0.000713	CcSEcCtD
Lisuride—Dyspnoea—Topiramate—obesity	7.67e-05	0.000703	CcSEcCtD
Lisuride—Somnolence—Topiramate—obesity	7.65e-05	0.000701	CcSEcCtD
Lisuride—Decreased appetite—Topiramate—obesity	7.48e-05	0.000685	CcSEcCtD
Lisuride—Gastrointestinal disorder—Topiramate—obesity	7.43e-05	0.00068	CcSEcCtD
Lisuride—Fatigue—Topiramate—obesity	7.42e-05	0.000679	CcSEcCtD
Lisuride—Constipation—Topiramate—obesity	7.36e-05	0.000674	CcSEcCtD
Lisuride—CYP3A4—liver—obesity	7.32e-05	0.00678	CbGeAlD
Lisuride—Ergotamine—HTR2A—obesity	7.22e-05	0.0189	CrCbGaD
Lisuride—CYP2D6—liver—obesity	7.21e-05	0.00667	CbGeAlD
Lisuride—Feeling abnormal—Topiramate—obesity	7.09e-05	0.000649	CcSEcCtD
Lisuride—Asthenia—Topiramate—obesity	6.17e-05	0.000565	CcSEcCtD
Lisuride—Dizziness—Topiramate—obesity	5.69e-05	0.000521	CcSEcCtD
Lisuride—Vomiting—Topiramate—obesity	5.47e-05	0.000501	CcSEcCtD
Lisuride—Headache—Topiramate—obesity	5.39e-05	0.000494	CcSEcCtD
Lisuride—DRD2—Signaling Pathways—SERPINE1—obesity	9.83e-07	9.2e-06	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MTOR—obesity	9.81e-07	9.18e-06	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—PIK3CB—obesity	9.81e-07	9.18e-06	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PIK3CD—obesity	9.77e-07	9.15e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—GOT2—obesity	9.74e-07	9.12e-06	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—MAPK8—obesity	9.69e-07	9.08e-06	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—PIK3CA—obesity	9.69e-07	9.07e-06	CbGpPWpGaD
Lisuride—HTR2A—GPCR downstream signaling—PIK3CA—obesity	9.68e-07	9.06e-06	CbGpPWpGaD
Lisuride—DRD1—Signaling by GPCR—AKT1—obesity	9.67e-07	9.05e-06	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—SERPINE1—obesity	9.67e-07	9.05e-06	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—POMC—obesity	9.63e-07	9.01e-06	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—INS—obesity	9.58e-07	8.96e-06	CbGpPWpGaD
Lisuride—ADRB1—GPCR downstream signaling—AKT1—obesity	9.57e-07	8.96e-06	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—MAPK8—obesity	9.57e-07	8.95e-06	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—MAPK8—obesity	9.57e-07	8.95e-06	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—TYK2—obesity	9.56e-07	8.95e-06	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—PIK3CB—obesity	9.54e-07	8.93e-06	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MTOR—obesity	9.54e-07	8.93e-06	CbGpPWpGaD
Lisuride—ADRA1D—Signaling by GPCR—AKT1—obesity	9.54e-07	8.93e-06	CbGpPWpGaD
Lisuride—DRD3—Signaling by GPCR—AKT1—obesity	9.54e-07	8.93e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—FASN—obesity	9.53e-07	8.92e-06	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—MYC—obesity	9.49e-07	8.89e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—BCHE—obesity	9.49e-07	8.89e-06	CbGpPWpGaD
Lisuride—ADRA2B—GPCR downstream signaling—AKT1—obesity	9.48e-07	8.88e-06	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—RHOA—obesity	9.48e-07	8.87e-06	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—TGFB1—obesity	9.47e-07	8.87e-06	CbGpPWpGaD
Lisuride—ADRB1—Signaling by GPCR—IL6—obesity	9.42e-07	8.82e-06	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CCL2—obesity	9.42e-07	8.82e-06	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—TYK2—obesity	9.4e-07	8.8e-06	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—STAT3—obesity	9.4e-07	8.8e-06	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MTOR—obesity	9.39e-07	8.79e-06	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—PIK3CB—obesity	9.39e-07	8.79e-06	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—MTHFR—obesity	9.38e-07	8.78e-06	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—PIK3R1—obesity	9.38e-07	8.78e-06	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—NOS3—obesity	9.38e-07	8.78e-06	CbGpPWpGaD
Lisuride—ADRA2B—Signaling by GPCR—IL6—obesity	9.34e-07	8.74e-06	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—RHOA—obesity	9.33e-07	8.73e-06	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—IL6—obesity	9.32e-07	8.72e-06	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—MYC—obesity	9.3e-07	8.7e-06	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—TGFB1—obesity	9.27e-07	8.68e-06	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—PIK3CB—obesity	9.27e-07	8.68e-06	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—IGF1—obesity	9.26e-07	8.67e-06	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—AKT2—obesity	9.26e-07	8.66e-06	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—NOS3—obesity	9.23e-07	8.64e-06	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PIK3R1—obesity	9.23e-07	8.64e-06	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PPARA—obesity	9.21e-07	8.62e-06	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—PTGS2—obesity	9.19e-07	8.6e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—CYP2E1—obesity	9.16e-07	8.57e-06	CbGpPWpGaD
Lisuride—HTR1A—GPCR downstream signaling—AKT1—obesity	9.16e-07	8.57e-06	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—MYC—obesity	9.15e-07	8.56e-06	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—TGFB1—obesity	9.13e-07	8.54e-06	CbGpPWpGaD
Lisuride—HTR2C—GPCR downstream signaling—AKT1—obesity	9.11e-07	8.53e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—NQO1—obesity	9.06e-07	8.48e-06	CbGpPWpGaD
Lisuride—HTR1A—Signaling by GPCR—IL6—obesity	9.01e-07	8.44e-06	CbGpPWpGaD
Lisuride—HTR2C—Signaling by GPCR—IL6—obesity	8.97e-07	8.39e-06	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MMP9—obesity	8.96e-07	8.39e-06	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—PIK3CA—obesity	8.94e-07	8.36e-06	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—AGT—obesity	8.92e-07	8.35e-06	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PIK3CD—obesity	8.89e-07	8.33e-06	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MMP9—obesity	8.88e-07	8.31e-06	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—STAT3—obesity	8.86e-07	8.3e-06	CbGpPWpGaD
Lisuride—ADRA2C—GPCR downstream signaling—AKT1—obesity	8.86e-07	8.29e-06	CbGpPWpGaD
Lisuride—ADRA2A—GPCR downstream signaling—PIK3CA—obesity	8.81e-07	8.25e-06	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—SERPINE1—obesity	8.8e-07	8.23e-06	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—PIK3CA—obesity	8.79e-07	8.23e-06	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—STAT3—obesity	8.75e-07	8.19e-06	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—STAT3—obesity	8.75e-07	8.19e-06	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—APOE—obesity	8.74e-07	8.18e-06	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—MYC—obesity	8.73e-07	8.18e-06	CbGpPWpGaD
Lisuride—ADRA2C—Signaling by GPCR—IL6—obesity	8.72e-07	8.16e-06	CbGpPWpGaD
Lisuride—ADRA1B—GPCR downstream signaling—AKT1—obesity	8.72e-07	8.16e-06	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MAPK8—obesity	8.72e-07	8.16e-06	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—TGFB1—obesity	8.71e-07	8.16e-06	CbGpPWpGaD
Lisuride—ADRB1—Signaling by GPCR—AKT1—obesity	8.69e-07	8.14e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—GCG—obesity	8.68e-07	8.13e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—SLC2A4—obesity	8.68e-07	8.13e-06	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—PIK3CB—obesity	8.66e-07	8.11e-06	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MTOR—obesity	8.66e-07	8.11e-06	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—CAV1—obesity	8.65e-07	8.1e-06	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MAPK8—obesity	8.64e-07	8.08e-06	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—APOA1—obesity	8.64e-07	8.08e-06	CbGpPWpGaD
Lisuride—ADRA2B—Signaling by GPCR—AKT1—obesity	8.61e-07	8.06e-06	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—AKT1—obesity	8.6e-07	8.05e-06	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—IL6—obesity	8.58e-07	8.03e-06	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MMP9—obesity	8.57e-07	8.02e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—CYCS—obesity	8.57e-07	8.02e-06	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—TYK2—obesity	8.56e-07	8.01e-06	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MMP9—obesity	8.53e-07	7.98e-06	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PIK3CB—obesity	8.52e-07	7.98e-06	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MTOR—obesity	8.52e-07	7.98e-06	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—RHOA—obesity	8.48e-07	7.94e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—GOT1—obesity	8.41e-07	7.87e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—GGT1—obesity	8.41e-07	7.87e-06	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PIK3R1—obesity	8.4e-07	7.86e-06	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—NOS3—obesity	8.4e-07	7.86e-06	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MAPK8—obesity	8.34e-07	7.8e-06	CbGpPWpGaD
Lisuride—HTR1A—Signaling by GPCR—AKT1—obesity	8.31e-07	7.78e-06	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MMP9—obesity	8.29e-07	7.77e-06	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MAPK8—obesity	8.29e-07	7.76e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—NCOA1—obesity	8.28e-07	7.75e-06	CbGpPWpGaD
Lisuride—HTR2C—Signaling by GPCR—AKT1—obesity	8.27e-07	7.74e-06	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—MYC—obesity	8.24e-07	7.71e-06	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—TGFB1—obesity	8.22e-07	7.69e-06	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MMP9—obesity	8.16e-07	7.64e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—CYP19A1—obesity	8.16e-07	7.64e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—STK11—obesity	8.16e-07	7.64e-06	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—MYC—obesity	8.13e-07	7.61e-06	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—MYC—obesity	8.13e-07	7.61e-06	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—TGFB1—obesity	8.11e-07	7.59e-06	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—TGFB1—obesity	8.11e-07	7.59e-06	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MAPK8—obesity	8.07e-07	7.55e-06	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—PIK3CA—obesity	8.06e-07	7.55e-06	CbGpPWpGaD
Lisuride—ADRA2C—Signaling by GPCR—AKT1—obesity	8.04e-07	7.53e-06	CbGpPWpGaD
Lisuride—DRD2—GPCR downstream signaling—AKT1—obesity	8.04e-07	7.53e-06	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—PIK3CA—obesity	8e-07	7.49e-06	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—STAT3—obesity	7.97e-07	7.46e-06	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MAPK8—obesity	7.94e-07	7.43e-06	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—AKT1—obesity	7.92e-07	7.41e-06	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—IL6—obesity	7.91e-07	7.41e-06	CbGpPWpGaD
Lisuride—HTR2A—GPCR downstream signaling—AKT1—obesity	7.91e-07	7.4e-06	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—STAT3—obesity	7.9e-07	7.39e-06	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—PIK3CA—obesity	7.89e-07	7.39e-06	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CG—obesity	7.88e-07	7.38e-06	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—IL6—obesity	7.79e-07	7.29e-06	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—PIK3CA—obesity	7.77e-07	7.27e-06	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PIK3CB—obesity	7.75e-07	7.26e-06	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MTOR—obesity	7.75e-07	7.26e-06	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—STAT3—obesity	7.62e-07	7.13e-06	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PPARG—obesity	7.61e-07	7.12e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—COMT—obesity	7.59e-07	7.1e-06	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—STAT3—obesity	7.58e-07	7.1e-06	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MMP9—obesity	7.53e-07	7.05e-06	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—POMC—obesity	7.5e-07	7.02e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—GNB3—obesity	7.48e-07	7.01e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PPARGC1A—obesity	7.48e-07	7.01e-06	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—INS—obesity	7.46e-07	6.99e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—HMOX1—obesity	7.45e-07	6.97e-06	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—PIK3CA—obesity	7.41e-07	6.94e-06	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MMP9—obesity	7.41e-07	6.93e-06	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MYC—obesity	7.4e-07	6.93e-06	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—TGFB1—obesity	7.39e-07	6.91e-06	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—STAT3—obesity	7.38e-07	6.9e-06	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MYC—obesity	7.34e-07	6.87e-06	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MAPK8—obesity	7.32e-07	6.85e-06	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—TGFB1—obesity	7.32e-07	6.85e-06	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—AKT1—obesity	7.3e-07	6.83e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—GNAS—obesity	7.29e-07	6.82e-06	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—STAT3—obesity	7.26e-07	6.79e-06	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MAPK8—obesity	7.2e-07	6.74e-06	CbGpPWpGaD
Lisuride—ADRA2A—GPCR downstream signaling—AKT1—obesity	7.2e-07	6.74e-06	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—AKT1—obesity	7.18e-07	6.72e-06	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—IL6—obesity	7.14e-07	6.68e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—APOB—obesity	7.14e-07	6.68e-06	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—IL6—obesity	7.08e-07	6.63e-06	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MYC—obesity	7.08e-07	6.63e-06	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—TGFB1—obesity	7.06e-07	6.61e-06	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MYC—obesity	7.05e-07	6.6e-06	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—TGFB1—obesity	7.03e-07	6.58e-06	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—PIK3CA—obesity	6.99e-07	6.54e-06	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—IL6—obesity	6.99e-07	6.54e-06	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—PIK3CA—obesity	6.96e-07	6.51e-06	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CD—obesity	6.93e-07	6.49e-06	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—PIK3CA—obesity	6.9e-07	6.46e-06	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—PIK3CA—obesity	6.9e-07	6.46e-06	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—IL6—obesity	6.88e-07	6.44e-06	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MYC—obesity	6.85e-07	6.42e-06	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—ALB—obesity	6.84e-07	6.4e-06	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—TGFB1—obesity	6.84e-07	6.4e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—LPL—obesity	6.81e-07	6.38e-06	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MYC—obesity	6.74e-07	6.31e-06	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MMP9—obesity	6.74e-07	6.31e-06	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—TGFB1—obesity	6.73e-07	6.3e-06	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—STAT3—obesity	6.69e-07	6.26e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—GPX1—obesity	6.65e-07	6.22e-06	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—AKT1—obesity	6.58e-07	6.16e-06	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—STAT3—obesity	6.58e-07	6.16e-06	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—IL6—obesity	6.56e-07	6.15e-06	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MAPK8—obesity	6.55e-07	6.13e-06	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3R1—obesity	6.54e-07	6.13e-06	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—NOS3—obesity	6.54e-07	6.13e-06	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—AKT1—obesity	6.53e-07	6.12e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—CD36—obesity	6.47e-07	6.06e-06	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—AKT1—obesity	6.45e-07	6.04e-06	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—AKT1—obesity	6.34e-07	5.94e-06	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—PIK3CA—obesity	6.29e-07	5.88e-06	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—PIK3CA—obesity	6.23e-07	5.83e-06	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MYC—obesity	6.22e-07	5.82e-06	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—TGFB1—obesity	6.2e-07	5.81e-06	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—IL6—obesity	6.19e-07	5.8e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—MTHFR—obesity	6.13e-07	5.74e-06	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MYC—obesity	6.12e-07	5.73e-06	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—IL6—obesity	6.11e-07	5.72e-06	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—IL6—obesity	6.11e-07	5.72e-06	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—TGFB1—obesity	6.1e-07	5.71e-06	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—AKT1—obesity	6.06e-07	5.67e-06	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CB—obesity	6.04e-07	5.65e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PPARA—obesity	6.02e-07	5.63e-06	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—PIK3CA—obesity	6.01e-07	5.63e-06	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—STAT3—obesity	5.99e-07	5.61e-06	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PTGS2—obesity	5.99e-07	5.6e-06	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—PIK3CA—obesity	5.98e-07	5.6e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—AGT—obesity	5.83e-07	5.46e-06	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—PIK3CA—obesity	5.82e-07	5.45e-06	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—PIK3CA—obesity	5.73e-07	5.36e-06	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—AKT1—obesity	5.71e-07	5.35e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—APOE—obesity	5.71e-07	5.35e-06	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—AKT1—obesity	5.68e-07	5.32e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—CAV1—obesity	5.66e-07	5.3e-06	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—PIK3CA—obesity	5.65e-07	5.29e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—APOA1—obesity	5.65e-07	5.29e-06	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—AKT1—obesity	5.64e-07	5.28e-06	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—AKT1—obesity	5.64e-07	5.28e-06	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MYC—obesity	5.57e-07	5.21e-06	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—IL6—obesity	5.57e-07	5.21e-06	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—TGFB1—obesity	5.55e-07	5.2e-06	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—IL6—obesity	5.51e-07	5.16e-06	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—IL6—obesity	5.32e-07	4.98e-06	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—IL6—obesity	5.3e-07	4.96e-06	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—PIK3CA—obesity	5.28e-07	4.94e-06	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PIK3CA—obesity	5.19e-07	4.86e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CG—obesity	5.15e-07	4.82e-06	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—IL6—obesity	5.15e-07	4.82e-06	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—AKT1—obesity	5.13e-07	4.81e-06	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—AKT1—obesity	5.09e-07	4.76e-06	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—IL6—obesity	5.07e-07	4.75e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PPARG—obesity	4.97e-07	4.66e-06	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—AKT1—obesity	4.91e-07	4.6e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—POMC—obesity	4.91e-07	4.59e-06	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—AKT1—obesity	4.89e-07	4.57e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—INS—obesity	4.88e-07	4.57e-06	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—AKT1—obesity	4.75e-07	4.45e-06	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PIK3CA—obesity	4.73e-07	4.42e-06	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—AKT1—obesity	4.68e-07	4.38e-06	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—IL6—obesity	4.67e-07	4.38e-06	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—AKT1—obesity	4.62e-07	4.32e-06	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—IL6—obesity	4.6e-07	4.31e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CD—obesity	4.53e-07	4.24e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—ALB—obesity	4.47e-07	4.19e-06	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—AKT1—obesity	4.31e-07	4.04e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3R1—obesity	4.28e-07	4.01e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—NOS3—obesity	4.28e-07	4.01e-06	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—AKT1—obesity	4.24e-07	3.97e-06	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—IL6—obesity	4.18e-07	3.92e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CB—obesity	3.95e-07	3.7e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PTGS2—obesity	3.91e-07	3.66e-06	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—AKT1—obesity	3.86e-07	3.61e-06	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CA—obesity	3.68e-07	3.45e-06	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—AKT1—obesity	3.01e-07	2.82e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CA—obesity	2.41e-07	2.25e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—AKT1—obesity	1.97e-07	1.84e-06	CbGpPWpGaD
